Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event

Incyte Corporation (Nasdaq:INCY) will host an investor and analyst event in New York City today to provide a comprehensive update on the Company’s growth opportunities and late-stage development portfolio.

“The presentations today are intended to highlight our diversified development portfolio and its potential to accelerate our top-line growth in the near term,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “The success of the REACH1 study of Jakafi in steroid-refractory acute graft-versus-host disease (GVHD) announced earlier today is excellent news for patients, and also further reinforces the potential of JAK inhibition in GVHD and our development strategy to address this devastating disease. We will also discuss our strategies to extend our leadership in the treatment of myeloproliferative neoplasms, as well as present recent data emerging from our research and development programs for our FGFR inhibitor in cholangiocarcinoma and bladder cancer, and positive results from a randomized Phase 2 study of topical ruxolitinib in patients with atopic dermatitis.”

A live webcast of the 2018 investor and analyst event will begin at 1:00 p.m. EDT. The live webcast and slide deck will be available via the Events & Presentations page under the Investor section of Incyte’s website at www.incyte.com. A replay will be available following the event.

Key Highlights

COMFORT – Extending leadership in myeloproliferative neoplasms (MPNs)

Jakafi^® (ruxolitinib) has transformed the lives of thousands of patients with MPNs since it was launched in the U.S. in 2011. However, there remain certain patients with MPNs that may have an inadequate response to, or are unable to tolerate, Jakafi monotherapy at its currently approved doses. These patients represent an R&D priority for Incyte—clinical trials are ongoing to evaluate combination strategies with Jakafi and Incyte molecules, as are discovery efforts to identify de novo drug targets that may become future therapeutic options that further improve outcomes and control the burden of disease for patients with MPNs.

REACH – Jakafi (ruxolitinib, JAK1/JAK2) in steroid-refractory GVHD

As announced earlier today, the REACH1 pivotal trial of ruxolitinib in combination with corticosteroids for the treatment of patients with steroid-refractory acute GVHD met its primary endpoint. Based on these data, Incyte plans to file a supplemental New Drug Application (sNDA) for the approval of ruxolitinib for the treatment of steroid-refractory acute GVHD with the U.S. Food and Drug Administration (FDA) during the third quarter of 2018.